<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552149</url>
  </required_header>
  <id_info>
    <org_study_id>BINGO</org_study_id>
    <secondary_id>CSET 1287</secondary_id>
    <nct_id>NCT00552149</nct_id>
  </id_info>
  <brief_title>Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin</brief_title>
  <official_title>A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination With Cetuximab in Patients With Advanced Biliary Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin&#xD;
      Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BINGO trial is an open-label randomized phase II study evaluating the efficacy and&#xD;
      tolerance of gemcitabine-oxaliplatin combination chemotherapy (GEMOX regimen) alone or in&#xD;
      combination with cetuximab in patients (pts) with ABC. The BINGO study also comprises&#xD;
      ancillary translational research and functional imaging studies which aim to identify markers&#xD;
      predictive for treatment efficacy in ABC.&#xD;
&#xD;
      All eligible pts will be randomized 1:1 to receive:&#xD;
&#xD;
        -  Arm A: GEMOX alone every two weeks.&#xD;
&#xD;
        -  Arm B: GEMOX + cetuximab every two weeks.&#xD;
&#xD;
      Randomization will be stratified according to:&#xD;
&#xD;
        1. tumor stage (locally advanced vs metastatic),&#xD;
&#xD;
        2. primary tumor location (gallbladder vs non-gallbladder),&#xD;
&#xD;
        3. prior treatments (surgery or radiotherapy or brachytherapy or photodynamic therapy [PDT]&#xD;
           or adjuvant chemotherapy vs none),&#xD;
&#xD;
        4. center. EGFR tumor status has to be assessed for every pt by immunohistochemistry (IHC)&#xD;
           using biopsy or surgical material, at any time prior to inclusion into the study, but it&#xD;
           is neither an inclusion/exclusion criterion nor a stratification factor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of treatment efficacy by assessing the crude progression-free survival (PFS) rate at 4 months</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of feasibility and toxicity of the treatments</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of rate and duration of objective tumor response</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of rate and duration of tumor control (objective responses and stabilizations)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of PFS and over</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Advanced Biliary Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GEMOX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEMOX + CETUXIMAB</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemox, Cetuximab</intervention_name>
    <description>GEMOX (Arms 1 and 2), every two weeks:&#xD;
Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h&#xD;
Cetuximab (ErbituxÒ) (Arm B only) every two weeks:&#xD;
(chemotherapy will be started one hour after the end of the cetuximab infusion).&#xD;
Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adenocarcinoma of the biliary tract (gallbladder, intra and/or extrahepatic bile&#xD;
             ducts, or ampulla of Vater):&#xD;
&#xD;
               -  Cytologically or histologically confirmed. In case of uncertain biliary tract&#xD;
                  origin (e.g., intrahepatic, peripheral cholangiocarcinomas), inclusion is&#xD;
                  possible if i) extensive search for primary (thoracic and abdominopelvic CT scan,&#xD;
                  colonoscopy, upper digestive endoscopy, serum PSA level for men or mammography&#xD;
                  for women, and FDG-PET if possible) is negative; and ii) histological examination&#xD;
                  is consistent with bile duct adenocarcinoma (IHC should ideally be performed and&#xD;
                  be consistent with biliary primary, e.g., positive for cytokeratin 7 and 19 and&#xD;
                  negative for cytokeratin 20).&#xD;
&#xD;
               -  not amenable to curative resection, or recurrent after resection (i.e., locally&#xD;
                  advanced or metastatic),&#xD;
&#xD;
               -  With at least one unidimensionally measurable target lesion in a non-irradiated,&#xD;
                  non-PDT-treated area (longest diameter 1 cm [spiral CT scan]), or 2 cm&#xD;
                  [conventional CT scan]).&#xD;
&#xD;
               -  With biliary obstruction controlled,&#xD;
&#xD;
          2. Age between 18 and 75 years.&#xD;
&#xD;
          3. World Health Organization (WHO) performance status of 0 or 1.&#xD;
&#xD;
          4. Life expectancy higher than 3 months.&#xD;
&#xD;
          5. No prior chemotherapy for advanced disease. Previous adjuvant chemotherapy is allowed&#xD;
             (completed at least 6 months previously, if containing gemcitabine or platinum salts).&#xD;
             Previous irradiation (external radiotherapy, brachytherapy) and PDT are allowed&#xD;
             provided that there is at least one unidimensionally measurable target lesion in&#xD;
             untreated area.&#xD;
&#xD;
          6. Bilirubin 3 times the upper limit of the normal range (ULN). Pts with jaundice or&#xD;
             evidence of bile duct obstruction, in whom the biliary tree can be decompressed by&#xD;
             endoscopic or percutaneous endoprothesis with subsequent reduction in bilirubin £ 3&#xD;
             ULN, will be eligible for the study.&#xD;
&#xD;
          7. Aminotransferases (AST, ALT) 5 ULN, INR &lt; 1.5 (following vitamin K1 injection in&#xD;
             patients with current or recent history of jaundice or bile duct obstruction),&#xD;
             creatinine 1.5 ULN, neutrophils 1.5 109/L, platelets 100 109/L, hemoglobin 9 g/dL (red&#xD;
             blood cell transfusion if needed is allowed).&#xD;
&#xD;
          8. Written informed consent. Note: EGFR tumor status has to be known for every pt, but it&#xD;
             is neither an inclusion/exclusion criterion nor a stratification factor. EGFR&#xD;
             expression has to be assessed by IHC using biopsy or surgical material, at any time&#xD;
             prior to inclusion into the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known central nervous system metastases.&#xD;
&#xD;
          2. Contraindication or history of grade 3-4 allergy reaction to one treatment component.&#xD;
&#xD;
          3. Surgery (except diagnostic biopsy), external radiotherapy, brachytherapy, or PDT&#xD;
             within 30 days prior to start of treatment. Prior adjuvant chemotherapy is only&#xD;
             allowed if completed at least 30 days previously (6 months if containing gemcitabine&#xD;
             or platinum salts).&#xD;
&#xD;
          4. Participation in another clinical trial within 30 days prior to start of treatment.&#xD;
&#xD;
          5. Concomitant systemic chronic immunotherapy, chemotherapy, or antitumor hormone&#xD;
             therapy.&#xD;
&#xD;
          6. Previous administration of EGFR inhibitors or EGF.&#xD;
&#xD;
          7. Active uncontrolled infection, peripheral neuropathy grade 2, acute or subacute bowel&#xD;
             obstruction or history of inflammatory bowel disease, symptomatic coronary disease or&#xD;
             myocardial infarction in the past 6 months, congestive heart failure (NYHA class II),&#xD;
             interstitial pneumonitis or respiratory failure, or renal failure.&#xD;
&#xD;
          8. Pregnancy (or positive b-HCG dosage at baseline), breast-feeding, or lack of effective&#xD;
             contraception in male or female pts of reproductive potential.&#xD;
&#xD;
          9. Other malignancies either currently active or in the last 5 years, except adequately&#xD;
             treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma.&#xD;
&#xD;
         10. Legal incapacity or physical, psychological or mental status interfering with the pt's&#xD;
             ability to terminate the study or to sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David MALKA, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>October 31, 2007</study_first_submitted>
  <study_first_submitted_qc>October 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2007</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

